Melitracen Hydrochloride: Structure, Synthesis, Mechanism, and Pharmaceutical Insights

What is Melitracen Hydrochloride?

Melitracen hydrochloride, also known as melitracen HCl, is an anthracene-derivative tricyclic antidepressant (TCA). It is a popular drug in neuropsychiatric disorders and indications, including depression, anxiety, and fatigue. The generic drug name is 3-(10,10-dimethylanthracen-9-methylene)-N,N-dimethylpropan-1-amine hydrochloride. This article will cover the physicochemical properties of melitracen HCl, the synthetic route and mechanism of action, pharmacokinetics/pharmacodynamics, formulation considerations, analytical methods, and emerging process development.

Alfa Chemistry also has high-purity melitracen HCl available. Our products are synthesized with precision and fully characterized to assist in your research, formulation development, and pharmaceutical applications.

Catalog Number	Product Name
ACM10563709	Melitracen hydrochloride

To start, let's look at the physicochemical properties of melitracen HCl. From a materials chemistry perspective, melitracen HCl has the following key properties:

• Chemical structure: C₂₁H₂₆ClN (i.e., C₂₁H₂₅N·HCl), molecular weight approx. 327.89 g mol^-1.
• Physical form: white to off-white crystalline solid with a melting point of approx. 245-248°C.
• Solubility: While nominally a "solid," recent data suggest relatively high solubility in some solvents: e.g., in DMSO at 25°C, it is approximately 65 mg/mL (approx. 198 mM). Water solubility is relatively low (approx. 2 mg/mL).
• Structural class: Anthracen-based compound (10,10-dimethylanthrone core) with a dimethylaminopropyl side chain. Similar in structural scaffold to other tricyclic antidepressants (e.g., imipramine) but with different substituents.
• Classification: Non-selective monoamine reuptake inhibitor, ATC code N06AA14.
• Stability/Handling: Store at 4°C and use in pure solid form (salt form is standard).

For the materials chemist working in formulation or process research on the Alfa Chemistry advanced API platform, the physicochemical parameters listed above (e.g., solubility, crystallinity, melting point, molecular structure) provide guidance in selecting the appropriate downstream options for dosage form development, analytical methods, or custom synthesis.

How Is Melitracen Hydrochloride Synthesized?

In the field of process chemistry, the synthesis of melitracen HCl has been described in the literature. This synthetic route comprises four key steps:

A. Grignard addition of 10,10-dimethylanthrone (10,10-DMA) to 3-(N,N-dimethylamino)propylmagnesium chloride (DMPC-MgCl) generates a magnesium alkoxide intermediate.

B. Hydrolysis of the magnesium alkoxide yields the corresponding alcohol intermediate.

C. Dehydration of the alcohol forms the key propenylanthracene core (9-methylene moiety).

D. Final salt formation: Crystallization of the free base with hydrochloric acid yields melitracen hydrochloride.

The reported flow process simplifies earlier batch processes by eliminating the phase separation step, using tetrahydrofuran (THF) as the sole solvent, and operating at room temperature, thereby improving process efficiency and material throughput.

Fig.1 Flow synthesis of melitracen HC^[1].

What Is the Pharmacological Mechanism of Action of Melitracen HCl?

Melitracen HCl, from the point of view of medicinal chemistry and neuropharmacology, has the following therapeutic action:

• A TCA that blocks the reuptake of serotonin (5-HT) and norepinephrine (NE) from the synaptic cleft into the presynaptic nerve terminal.
• A higher concentration of 5-HT and NE in the synaptic cleft can enhance mood, have an anxiolytic effect, and reduce fatigue symptoms.
• Secondary pharmacological effects: due to weak affinity for histaminergic, adrenergic (α₁), and cholinergic (muscarinic) receptors, it has sedative, orthostatic hypotensive, and anticholinergic side effects.
• It is similar to imipramine but with a dimethylanthracene core as the main structural feature; other differences in substituents may also affect pharmacokinetic and receptor-binding properties.

Fig.2 The mechanisms of action of different drugs in the symptomatic treatment of patients with myasthenia gravis. Monarsen is an antisense oligodeoxynucleotide that inhibits the expression of the acetylcholinesterase receptor (AChE-R), the isoform of acetylcholinesterase predominant in patients with myasthenia gravis^[2].

What Are the Uses and Indications of Melitracen HCl?

Melitracen HCl is used in clinical practice, according to the indication, to treat mild to moderate depression, anxiety, fatigue, and some psychosomatic disorders. Important Points:

• It can be prescribed alone or in combination with an antipsychotic (for example, flupentixol) as part of a fixed-dose combination (for example, 10 mg of melitracen + 0.5 mg of flupentixol) for the treatment of depressive-anxiety disorders.
• The standard adult dose (melitracen monotherapy) is about 25 mg, up to two to three times a day, with a gradual increase in the dose as needed.
• Contraindications: recovery from myocardial infarction, narrow-angle glaucoma, use of a monoamine oxidase inhibitor (MAOI) within 14 days, epilepsy, bipolar affective disorder, and severe cardiac conduction disturbances.
• In non-psychiatric practice, the combination of melitracen and flupentixol was studied as an add-on treatment for gastrointestinal disorders in patients with psychosomatic diseases, such as irritable bowel syndrome or ulcerative colitis.

From the point of view of materials chemistry, the scope of indications is a parameter that determines the downstream requirements for the production of dosage forms, the compliance of the drug substance, the requirements for the stability of drugs, and the analysis of impurities.

How Should Melitracen HCl Be Formulated and Analyzed?

A. Formulation Considerations

• Given its moderate water solubility and solid melting point (approximately 245°C), melitracen hydrochloride is suitable for typical oral solid dosage forms—tablets or capsules.
• Its anticholinergic/adrenergic side effects suggest that, in certain markets, formulations should target controlled or extended release to mitigate peak release.
• The hydrochloride salt exhibits high water stability; however, excipient compatibility (particularly with moisture-sensitive adhesives or enteric coatings) requires evaluation.

B. Analytical and Quality Control Methods

Common assays include spectrophotometry, densitometry, HPLC-UV spectrophotometry, gas chromatography-mass spectrometry, and liquid chromatography-mass spectrometry. Impurity analysis should consider demethylation, deamination, or oxidation products; chromatographic separation and mass spectrometric detection are recommended.

C. Process and Material Controls

• Isolation of hydrochloride crystals requires careful crystallization control (e.g., solvent selection, seeding parameters, and cooling gradient) to ensure consistent crystal form, particle size distribution, and purity.
• Residual solvent monitoring is crucial; if THF or other solvents are used in the Grignard reaction step (e.g., in flow processes), ICH Q3C limits must be adhered to.

Safety and Adverse Effect Profile of Melitracen HCl

• Common adverse reactions: Anticholinergic symptoms (dry mouth, blurred vision, constipation), orthostatic hypotension (e.g., α₁₁ blockers), sedation/somnolence (e.g., histamine H₁₁ antagonists), and tachycardia.
• Use with caution in patients with cardiovascular disease, epilepsy, narrow-angle glaucoma, and pregnant or lactating women. Abrupt discontinuation may induce withdrawal symptoms; gradual dose reduction is recommended.
• Additive risks (e.g., extrapyramidal side effects of flupentixol, QT interval prolongation) must be considered when using combination therapy (melitracen + flupentixol).

Why Does Melitracen HCl Remain Important?

As newer antidepressants (e.g., SSRIs, SNRIs) with safer side effect profiles became available, melitracen HCl remained on the market only in a few countries where TCAs are still approved or as part of combination therapies (e.g., with flupentixol). However, from the point of view of materials chemistry, this molecule has some features of interest:

• Polymorph and salt screening: Although the hydrochloride is the only standard salt at present, other salts (e.g., mesylate, fumarate) may have superior solubility, stability or bioavailability profiles that would be worth exploring.
• Continuous flow scale-up: The continuous flow reactor modifications described here provide a ready-made technology for modernizing old, traditional TCA processes to achieve higher safety, reproducibility, and efficiency at reduced cost.
• Advanced formulations: As a highly lipophilic molecule, its advanced formulation techniques (e.g., solid dispersions, nanoparticles, enteric-coated SR formulations) may breathe new life into this TCA, especially in niche markets or formulations.
• Analytical Innovation: The molecularly imprinted (MIP)-based sensor approach described above is a practical example of materials chemistry applied to analytical chemistry to generate compact, high-throughput analytical methods for API and formulation quality control^[3].

In summary, melitracen HCl is a classic tricyclic antidepressant whose chemical structure, pharmacology, and manufacturing processes are closely related to materials chemistry. Alfa Chemistry, with its focus on advanced API supply and custom chemistry, has a deep understanding of this class of molecules—from physicochemical characterization and process design to analytical method development and formulation compatibility—providing strong product support for clients developing traditional or niche central nervous system (CNS) therapies.
Clients exploring melitracen hydrochloride may also find value in our following products:

References

1. Jiao J, et al. Multi‐Step Continuous‐Flow Organic Synthesis: Opportunities and Challenges. Chemistry – A European Journal.(2021).
2. Remijn-Nelissen L, et al. Symptomatic, pharmacological treatment of myasthenia gravis. RRNMF Neuromuscular Journal.(2023).
3. Abdallah NA, et al. Solid-Contact ISE for the Potentiometric Determination of Melitracen Hydrochloride in Pharmaceutical Tablets and Human Plasma. Journal of The Electrochemical Society.(2020).

Please kindly note that our products are for research use only.